Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 18c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.83), $0.18 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $37.96 million versus the consensus estimate of $27.13 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Jefferies Starts Bajaj Housing Finance (BAJAJHFL:IN) at Hold
• Webull Corp (BULL) Tops Q2 EPS by 1c